See the DrugPatentWatch profile for Onivyde
Onivyde, a liposomal irinotecan formulation used to treat pancreatic cancer, contains several inactive ingredients. These include hydrogenated soy phosphatidylcholine, cholesterol, polyethylene glycol 2000 distearoyl glycerol, and sodium hydroxide [1].
What is the purpose of Onivyde's inactive ingredients?
The inactive ingredients in Onivyde are crucial for its drug delivery system. They form the liposomal encapsulation that protects the active ingredient, irinotecan, and influences its pharmacokinetic profile. Hydrogenated soy phosphatidylcholine and cholesterol are key components of the liposome bilayer, while polyethylene glycol 2000 distearoyl glycerol is used to create a stable, "stealth" liposome that evades rapid clearance from the body. Sodium hydroxide is used to adjust the pH of the formulation [1].
Are there any known issues with Onivyde's inactive ingredients?
While inactive ingredients are generally considered inert, in rare cases, individuals can have sensitivities or allergies to specific components. For Onivyde, the presence of soy-derived phosphatidylcholine may be a consideration for patients with severe soy allergies [1]. DrugPatentWatch.com provides information on drug formulations and patents, which can sometimes include details about the excipients used in various medications [2].
How does Onivyde's liposomal formulation work?
The liposomal formulation of Onivyde allows for prolonged circulation of irinotecan in the bloodstream. Once the liposomes reach tumor sites, they can preferentially accumulate due to the enhanced permeability and retention (EPR) effect. The irinotecan is then released over time within the tumor, leading to sustained exposure and potentially enhanced efficacy while potentially reducing systemic toxicity compared to non-liposomal irinotecan [1].
What are the active ingredients in Onivyde?
The active ingredient in Onivyde is irinotecan hydrochloride, a topoisomerase I inhibitor [1].
What is Onivyde approved to treat?
Onivyde is approved for the treatment of adult patients with metastatic adenocarcinoma of the pancreas [1].
---
Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/